{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:37:49Z","timestamp":1788781069932,"version":"build-2803163510"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T00:00:00Z","timestamp":1695340800000},"content-version":"am","delay-in-days":325,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["32AG044296"],"award-info":[{"award-number":["32AG044296"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.jns.2022.120420","type":"journal-article","created":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T03:44:51Z","timestamp":1663040691000},"page":"120420","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Prognosis in substance abuse-related acute toxic leukoencephalopathy: A scoping review"],"prefix":"10.1016","volume":"442","author":[{"given":"Zachary A.","family":"Macchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara C.","family":"Carlisle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Filley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jns.2022.120420_bb0005","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1056\/NEJM200108093450606","article-title":"Toxic leukoencephalopathy","volume":"345","author":"Filley","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.jns.2022.120420_bb0010","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1176\/appi.neuropsych.17010006","article-title":"The expanding prominence of toxic leukoencephalopathy","volume":"29","author":"Filley","year":"2017","journal-title":"J. Neuropsychiatr. Clin. Neurosci."},{"issue":"8","key":"10.1016\/j.jns.2022.120420_bb0015","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1212\/WNL.53.8.1765","article-title":"Leukoencephalopathy and raised brain lactate from heroin vapor inhalation (\u201cchasing the dragon\u201d)","volume":"53","author":"Kriegstein","year":"1999","journal-title":"Neurology."},{"issue":"935","key":"10.1016\/j.jns.2022.120420_bb0020","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1259\/bjr\/61535842","article-title":"Chasing \u201cchasing the dragon\u201d with MRI: leukoencephalopathy in drug abuse","volume":"78","author":"Bartlett","year":"2005","journal-title":"Br. J. Radiol."},{"issue":"2","key":"10.1016\/j.jns.2022.120420_bb0025","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.crad.2007.07.021","article-title":"Heroin-induced leukoencephalopathy: characterization using MRI, diffusion-weighted imaging, and MR spectroscopy","volume":"63","author":"Offiah","year":"2008","journal-title":"Clin. Radiol."},{"issue":"1","key":"10.1016\/j.jns.2022.120420_bb0030","doi-asserted-by":"crossref","first-page":"192","DOI":"10.2214\/AJR.08.1176","article-title":"Acute toxic leukoencephalopathy: potential for reversibility clinically and on MRI with diffusion-weighted and FLAIR imaging","volume":"193","author":"McKinney","year":"2009","journal-title":"Am. J. Roentgenol."},{"issue":"7","key":"10.1016\/j.jns.2022.120420_bb0035","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci9070170","article-title":"White matter hyperintensity regression: comparison of brain atrophy and cognitive profiles with progression and stable groups","volume":"9","author":"Al-Janabi","year":"2019","journal-title":"Brain Sci."},{"issue":"7399","key":"10.1016\/j.jns.2022.120420_bb0040","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nature11007","article-title":"Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity","volume":"485","author":"F\u00fcnfschilling","year":"2012","journal-title":"Nature."},{"issue":"2","key":"10.1016\/j.jns.2022.120420_bb0045","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/glia.23706","article-title":"The fate and function of oligodendrocyte progenitor cells after traumatic spinal cord injury","volume":"68","author":"Duncan","year":"2020","journal-title":"Glia."},{"issue":"5","key":"10.1016\/j.jns.2022.120420_bb0050","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1172\/JCI94158","article-title":"A TLR\/AKT\/FoxO3 immune tolerance\u2013like pathway disrupts the repair capacity of oligodendrocyte progenitors","volume":"128","author":"Srivastava","year":"2018","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.jns.2022.120420_bb0055","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/ana.23788","article-title":"Digestion products of the PH20 hyaluronidase inhibit remyelination","volume":"73","author":"Preston","year":"2013","journal-title":"Ann. Neurol."},{"issue":"25","key":"10.1016\/j.jns.2022.120420_bb0060","doi-asserted-by":"crossref","first-page":"11555","DOI":"10.1073\/pnas.1006496107","article-title":"Hyaluronan blocks oligodendrocyte progenitor maturation and remyelination through TLR2","volume":"107","author":"Sloane","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.jns.2022.120420_bb0065","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41380-020-0661-4","article-title":"The changing opioid crisis: development, challenges and opportunities","volume":"26","author":"Volkow","year":"2021","journal-title":"Mol. Psychiatry"},{"issue":"14","key":"10.1016\/j.jns.2022.120420_bb0070","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1001\/jama.2015.11859","article-title":"Nonmedical prescription opioid use and use disorders among adults aged 18 through 64 years in the United States, 2003-2013","volume":"314","author":"Han","year":"2015","journal-title":"Jama."},{"key":"10.1016\/j.jns.2022.120420_bb0075","doi-asserted-by":"crossref","first-page":"113096","DOI":"10.1016\/j.psychres.2020.113096","article-title":"The COVID-19 pandemic and its impact on substance use: implications for prevention and treatment","volume":"289","author":"Ornell","year":"2020","journal-title":"Psychiatry Res."},{"issue":"1","key":"10.1016\/j.jns.2022.120420_bb0080","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/1364557032000119616","article-title":"Scoping studies: towards a methodological framework","volume":"8","author":"Arksey","year":"2005","journal-title":"Int. J. Soc. Res. Methodol."},{"issue":"3","key":"10.1016\/j.jns.2022.120420_bb0085","first-page":"141","article-title":"Guidance for conducting systematic scoping reviews","volume":"13","author":"Peters","year":"2015","journal-title":"JBI Evid. Implement."},{"issue":"2","key":"10.1016\/j.jns.2022.120420_bb0090","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3174\/ajnr.A5947","article-title":"Acute toxic leukoencephalopathy: etiologies, imaging findings, and outcomes in 101 patients","volume":"40","author":"\u00d6z\u00fctemiz","year":"2019","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"10.1016\/j.jns.2022.120420_bb0095","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jclinepi.2017.04.026","article-title":"CARE guidelines for case reports: explanation and elaboration document","volume":"89","author":"Riley","year":"2017","journal-title":"J. Clin. Epidemiol."},{"issue":"6","key":"10.1016\/j.jns.2022.120420_bb0100","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1177\/104973230201200611","article-title":"Matrix analysis as a complementary analytic strategy in qualitative inquiry","volume":"12","author":"Averill","year":"2002","journal-title":"Qual. Health Res."},{"issue":"4","key":"10.1016\/j.jns.2022.120420_bb0105","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.neuro.2011.03.005","article-title":"Recurrent leukoencephalopathy in a cocaine abuser","volume":"32","author":"Bianco","year":"2011","journal-title":"Neurotoxicology."},{"issue":"1","key":"10.1016\/j.jns.2022.120420_bb0110","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.neurol.2011.01.022","article-title":"Toxic leucoencephalopathy after use of sniffed heroin, an unrecognized form of beneficial evolution","volume":"168","author":"Hav\u00e9","year":"2012","journal-title":"Rev. Neurol. (Paris)"},{"issue":"3","key":"10.1016\/j.jns.2022.120420_bb0115","doi-asserted-by":"crossref","first-page":"565","DOI":"10.3174\/ajnr.A1889","article-title":"Methadone-induced toxic leukoencephalopathy: MR imaging and MR proton spectroscopy findings","volume":"31","author":"Salgado","year":"2010","journal-title":"AJNR Am. J. Neuroradiol."},{"issue":"3","key":"10.1016\/j.jns.2022.120420_bb0120","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/ADM.0000000000000470","article-title":"Toxic leukoencephalopathy presenting as lethal catatonia","volume":"13","author":"van Esch","year":"2019","journal-title":"J. Addict. Med."},{"issue":"11","key":"10.1016\/j.jns.2022.120420_bb0125","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1007\/s00415-010-5620-6","article-title":"Toxic leukoencephalopathy after intravenous heroin injection: a case with clinical and radiological reversibility","volume":"257","author":"Villella","year":"2010","journal-title":"J. Neurol."},{"issue":"6","key":"10.1016\/j.jns.2022.120420_bb0130","doi-asserted-by":"crossref","first-page":"e375","DOI":"10.1097\/ADM.0000000000000671","article-title":"Altered mental status: a case report of toxic leukoencephalopathy following heroin exposure","volume":"14","author":"Weitzer","year":"2020","journal-title":"J. Addict. Med."},{"issue":"9","key":"10.1016\/j.jns.2022.120420_bb0135","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1007\/s004150050469","article-title":"Toxic leukoencephalopathy after intravenous consumption of heroin and cocaine with unexpected clinical recovery","volume":"246","author":"Maschke","year":"1999","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.jns.2022.120420_bb0140","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1177\/1751143718774714","article-title":"Chasing the wrong dragon: a new presentation of heroin-induced toxic leukoencephalopathy mimicking anoxic brain injury","volume":"20","author":"Achamallah","year":"2019","journal-title":"J. Intensive Care Soc."},{"key":"10.1016\/j.jns.2022.120420_bb0145","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1477-7517-8-3","article-title":"Chasing the dragon - characterizing cases of leukoencephalopathy associated with heroin inhalation in British Columbia","volume":"8","author":"Buxton","year":"2011","journal-title":"Harm Reduct. J."},{"issue":"11","key":"10.1016\/j.jns.2022.120420_bb0150","first-page":"1484","article-title":"Fatal toxic leukoencephalopathy associated with consumption of pasta base of cocaine: report of three cases","volume":"143","author":"Cartier","year":"2015","journal-title":"Rev. Med. Chil."},{"issue":"2","key":"10.1016\/j.jns.2022.120420_bb0155","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s00415-018-9131-1","article-title":"Different routes of heroin intake cause various heroin-induced leukoencephalopathies","volume":"266","author":"Cheng","year":"2019","journal-title":"J. Neurol."},{"issue":"6","key":"10.1016\/j.jns.2022.120420_bb0160","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1177\/0310057X1404200615","article-title":"Toxic leukoencephalopathy in the intensive care unit","volume":"42","author":"Holyoak","year":"2014","journal-title":"Anaesth. Intensive Care"},{"issue":"7","key":"10.1016\/j.jns.2022.120420_bb0165","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1136\/jnnp.2004.047134","article-title":"Fatal toxic leukoencephalopathy: clinical, radiological, and necropsy findings in two patients","volume":"76","author":"Ryan","year":"2005","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"2","key":"10.1016\/j.jns.2022.120420_bb0170","article-title":"Delayed leukoencephalopathy: three case reports and a literature review","volume":"4","author":"Torralba-Mor\u00f3n","year":"2017","journal-title":"Eur. J. Case Rep. Intern. Med."},{"issue":"6","key":"10.1016\/j.jns.2022.120420_bb0175","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/ana.410230614","article-title":"Toluene abuse causes diffuse central nervous system white matter changes","volume":"23","author":"Rosenberg","year":"1988","journal-title":"Ann. Neurol."},{"issue":"Pt 3","key":"10.1016\/j.jns.2022.120420_bb0180","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/brain\/awg061","article-title":"Axonal damage: a key predictor of outcome in human CNS diseases","volume":"126","author":"Medana","year":"2003","journal-title":"Brain."},{"issue":"4","key":"10.1016\/j.jns.2022.120420_bb0185","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/j.1750-3639.1999.tb00547.x","article-title":"Axonal pathology in multiple sclerosis. A historical note","volume":"9","author":"Kornek","year":"1999","journal-title":"Brain Pathol."},{"issue":"11","key":"10.1016\/j.jns.2022.120420_bb0190","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nrn2480","article-title":"Remyelination in the CNS: from biology to therapy","volume":"9","author":"Franklin","year":"2008","journal-title":"Nat. Rev. Neurosci."},{"issue":"2","key":"10.1016\/j.jns.2022.120420_bb0195","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/jclp.20669","article-title":"Harm reduction therapy: a practice-friendly review of research","volume":"66","author":"Logan","year":"2010","journal-title":"J. Clin. Psychol."},{"key":"10.1016\/j.jns.2022.120420_bb0200","author":"U.S. Department of Health and Human Services (HHS) OotSG"},{"issue":"2","key":"10.1016\/j.jns.2022.120420_bb0205","article-title":"Clinical and MRI characteristics of levamisole-induced leukoencephalopathy in 16 patients. J neuroimaging 2009;13:326-331","volume":"21","author":"Gilbert","year":"2011","journal-title":"J. Neuroimaging"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X22002829?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X22002829?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T16:01:40Z","timestamp":1758384100000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X22002829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":41,"alternative-id":["S0022510X22002829"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2022.120420","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognosis in substance abuse-related acute toxic leukoencephalopathy: A scoping review","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2022.120420","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"120420"}}